BridgeBio Pharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BBIO | ALNY | IONS | BMRN | ROIV | GPCR | |
|---|---|---|---|---|---|---|
| Market cap | 15.17B | 21.57B | 6.67B | 11.07B | 27.61B | 1.45B |
| P/E (TTM) | — | 8.1 | — | — | — | — |
| Forward P/E | -225.0 | 14.4 | -35.0 | 9.0 | -27.5 | -9.6 |
| Price/book | -5.9 | 6.0 | 15.1 | 1.8 | 6.5 | 1.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +24.17% | −63.43% | −45.82% | +10.20% | +85.85% | −39.17% |
| Today | +5.21% | +0.74% | −0.67% | +2.64% | +6.08% | +0.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BBIO news ›First real-world look at acoramidis in Germany finds mostly first-line use in older patients
A German prescription database analysis of 289 patients found acoramidis was initiated mainly as first-line therapy for older, predominantly male patients with ATTR-CM, with intensification of several cardiovascular drug classes in the…
BRIJ Medical Closes Upsized $5M Financing Round, Led by Board with Strong Existing-Investor Participation
Nov 03, 2026, 15:37 ET Proceeds will fuel BRIJ Medical's continued commercial expansion of BRIJ-SEAL™ and the upcoming launch of BRIJ-Ag™, building on strong investor confidence and growing market momentum. SAN DIEGO, Nov. 3, 2026…
Should You Invest $1,000 in BridgeBio Pharma Right Now?
BridgeBio Pharma (BBIO +5.97%) is a biotech on the verge of a breakout. The company focuses on rare genetic diseases. It has only two approved therapies right now: Attruby and Nulibry. Attruby is the company's main earner right now. The…
Analyzing Arcus Biosciences (NYSE:RCUS) & BridgeBio Pharma (NASDAQ:BBIO)
Posted by Kim Johansen on Nov 3rd, 2026 Arcus Biosciences (NYSE:RCUS – Get Free Report) and BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
BridgeBio Pharma: BlackRock reports 5.1% stake
Palantir Reports Q3 2026 U.S. Comm Revenue Growth of 148% Y/Y and Revenue Growth of 96% Y/Y; Raises FY 2026 Revenue Guidance to 91% Y/Y Growth and U.S. Comm Revenue Guidance to 143% Y/Y, Crushing Consensus Expectations Aehr Test Systems…
BridgeBio Pharma Q3 2026 revenue rises to $353M
SEGG Media Reports More Than 1,500% Year-Over-Year Revenue Growth in Second Quarter, Driven by Veloce uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the…
Q3 revenue reaches $353M as BridgeBio Pharma (BBIO) narrows its net loss.
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease SEGG Media Reports More Than 1,500% Year-Over-Year Revenue Growth in Second…
Study Reports Positive Results for First Potential Oral Achondroplasia Therapy
Research By: Benjamin Cocanougher, MD, PhD Post Date: October 30, 2026 | Publish Date: June 28, 2026 Achondroplasia, the most common form of dwarfism, affects bone growth and can cause health complications beyond short stature. While…
What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
Posted by Mitch Edgeman on Nov 1st, 2026 BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter revenue growth driven by sales of ATTR cardiomyopathy treatment Attruby and a one-time milestone tied to European partner Bayer’s…
More from 1 other outlet
Morgan Stanley Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price
Posted by Defense World Staff on Oct 31st, 2026 BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price lifted by Morgan Stanley from $87.00 to $88.00 in a research note issued to investors on Friday morning,Benzinga reports. The…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com14
- stocktitan.net7
- themarketsdaily.com6
- markets.businessinsider.com5
- seekingalpha.com4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 59 articles, not a forecast.